Discussion AA is strongly associated with atopic diatheses, 4 and polymorphisms in
interleukin 4 (IL-4) and IL-13 have been described in patients with AA. 5, 6 The …

Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a
patient with atopic dermatitis Therefore, switching to a JAK inhibitor such as upadacitinib …

Atopic dermatitis (AD) is Th2-mediated with IL-4 and IL-13 predominance. 1 Dupilumab is
approved for moderate-to-severe adult AD. 1 TABLECases of dupilumab-induced psoriasis …

Alopecia areata has basically been understood as a type 1 inflammatory disease. Activated
NKG2D+ CD8+ cells produce the Th1 cytokine interferon‐γ, which leads to the disruption of …

DEAR EDITOR, Atopic dermatitis (AD) is a chronic itchy inflammatory skin condition
associated with significant impact on quality of life. AD is a complex disease involving …

Atopic dermatitis is an inflammatory skin disease, the prevalence of which has increased in
the last decade. It affects all age groups, with adult involvement being a major focus of …

Atopic dermatitis (AD) is a chronic eczematous disease with various types of rash, erythema,
edema/papulation, excoriation, or lichenification. Janus kinase 1 inhibitor upadacitinib is …

Background The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been
defined in clinical trials, but no real-world data are currently available. We aimed to assess …

To the Editor: We read with interest the article by Tracey et al 1 reporting on the
erythrodermic presentation of psoriasis in a patient treated with dupilumab. This Case …

Atopic dermatitis (AD) is an inflammatory skin condition affecting 3% to 10% of adults and
10% to 20% of children globally. 1 Systemic therapies such as cyclosporine, methotrexate …